Monday, October 22, 2018
- 9:00AM-11:00AM
-
Abstract Number: 1573
Salivary Dysbiosis Correlates with Clinical Status of Anti-Ro Positive Mothers of Children with Neonatal Lupus
Sjögren's Syndrome – Basic and Clinical Science Poster- 9:00AM-11:00AM
-
Abstract Number: 1572
Salivary Flow Rates and Oral Health Related Quality of Life Are Associated with Ultrasonographic Scoring of the Major Salivary Glands in Sjogren Syndrome
Sjögren's Syndrome – Basic and Clinical Science Poster- 9:00AM-11:00AM
-
Abstract Number: 1783
Salivary Gland Disease in IgG4-Related Disease Is Associated with Allergic Histories
Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease- 9:00AM-11:00AM
-
Abstract Number: 1225
Screening for Acquired Latent Tuberculosis in Patients with Rheumatoid Arthritis(RA) on Anti-Tnfα Therapy (TNF-I) in Southern California
Infection-related Rheumatic Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 1252
Screening for Tuberculosis before Initiating TNF Inhibitors: How Well Do We Do? a Nationwide Experience
Measures and Measurement of Healthcare Quality Poster II- 9:00AM-11:00AM
-
Abstract Number: 1189
Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean Perspective
Health Services Research Poster II – ACR/ARHP- 9:00AM-11:00AM
-
Abstract Number: 1091
Serine Arginine-Rich Splicing Factor 1 (SRSF1) Is Essential for T Lymphocyte Homeostasis and Decreased Levels of SRSF1 Correlate with Lymphopenia in SLE Patients
Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II- 9:00AM-11:00AM
-
Abstract Number: 1637
Serious Infections Among Psoriatic Arthritis Patients Taking TNF Inhibitors Versus Non-TNF Biologics: A Systematic Review and Network Meta-Analysis
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies- 9:00AM-11:00AM
-
Abstract Number: 1093
Serologic Evidence Linking Epstein Barr Virus Reactivation, Heightened Interferon Pathway Activation and Increased Disease Activity in Patients with Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II- 9:00AM-11:00AM
-
Abstract Number: 1221
Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards
Infection-related Rheumatic Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 1070
Seroreactivity Against Recombinant Citrullinated Myosin Is Associated with Measures of Diastolic Dysfunction in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Etiology and Pathogenesis Poster II- 9:00AM-11:00AM
-
Abstract Number: 1477
Serum Autoantibody Multi-Analyte Testing in Rheumatoid Arthritis Can Reduce Avoidable Costs Associated from False Positive Results. a Simulation Study in the United States of America
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis- 9:00AM-11:00AM
-
Abstract Number: 1680
Serum Calprotectin in Systemic Lupus Erythematosus: Is It a Good Activity Biomarker?
Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes- 9:00AM-11:00AM
-
Abstract Number: 1708
Serum Complement Regulatory Proteins and Disease Activity of Systemic Lupus Erythematosus